Form 4: BioMarin CFO Brian Mueller Acquires Shares Through RSU Vesting
SEC Form 4 Filing
EVP and CFO of BioMarin Pharmaceutical, Brian Mueller, reports acquisition of shares through vesting of Restricted Stock Units (RSUs) based on performance metrics.
Summary
- Brian Mueller, EVP and CFO of BioMarin Pharmaceutical, filed a Form 4 indicating changes in beneficial ownership.
- The reported transactions involve the acquisition of common stock through the vesting of Restricted Stock Units (RSUs).
- These RSUs were earned based on performance metrics related to total shareholder return, development goals, and core operating margin over the period of 2022-2024.
- A total of 11,040 RSUs were earned based on relative total shareholder return during 2022 through 2024.
- 9,660 RSUs were earned based on the number and nature of development goals achieved during 2022 through 2024.
- 9,367 RSUs were earned based on core operating margin over three, one-year periods spanning 2022 through 2024.
- The RSUs vest on March 15, 2025, subject to continued service.
- Following the reported transactions, Mueller beneficially owns 101,638 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The vesting of RSUs suggests performance targets were met, which is mildly positive, but it's not a major event.
Positives
- The vesting of RSUs indicates that performance goals were met, which could be viewed positively by investors.
- The CFO's increased stake in the company aligns his interests with those of shareholders.
Future Outlook
The RSUs will vest on March 15, 2025, subject to the reporting person's continued service through that date.
Industry Context
Form 4 filings are routine disclosures for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates compensation and ownership changes for a key executive at BioMarin.
Stakeholder Impact
- Shareholders may view the vesting of RSUs as a sign that the company is meeting its performance goals.
- Employees may be motivated by the fact that executives are being rewarded for their performance.
Key Dates
| Date | Description |
|---|---|
| 2022-2024 | Performance period for earning RSUs based on various metrics. |
| 02/25/2025 | Date of transaction (RSU vesting). |
| 02/27/2025 | Date of signature on the Form 4. |
| 03/15/2025 | Vesting date for the RSUs, subject to continued service. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.